Abstract: Objective The aim of this study was to investigate the efficacy and safety of sofosbuvir/velpatasvir (SOF/VEL) in treatment of patients with chronic hepatitis C (CHC) and hepatitis C precipitated liver cirrhosis in real-world study (RWS) in a single centre. Method This RWS included naïve or PR-treated patients with CHC, some concomitant with blood hypertension, diabetes, tumor or hepatitis, between May 2018 and April 2020. 32 patients with CHC and 36 patients with compensated hepatitis C -induced liver cirrhosis (CHC-CLC) received SOF/VEL for 12 weeks, and 31 patients with decompensated hepatitis C liver cirrhosis (CHC-DLC) or hepatocellular carcinoma received SOF/VEL and ribavirin (RBV) for 12 weeks. The HCV genotypes (GTs) were determined by RT-PCR. Results The prevalence of GT 2a(55.6%) and GT1b(34.3%) was dominant in our series; the early virological response (EVR4)in patients with CHC, CHC-CLC and CHC-DLC were 90.6%, 86.1% and 83.9%, the end of treatment (EOT) virologic response were 100.0% in the three groups, the sustained virological response (SVR) 12 and SVR24 in patients with CHC and CHC-CLC were 100.0% and 100.0% and both the SVR12 and SVR24 in patients with CHC-DLC were 93.5%, not significantly different among the three groups(P>0.05); both the SVR12 and SVR24 in our series was 97.8%, and they reached 100.0% when the patients with GT3b infection were excluded; the biochemical responses rates in the three groups were 87.5%, 83.3% and 74.2%, and the incidence of adverse event (AE) in our series was 12.1%, no severe AE or discontinuation of therapy owning to AE occurred. Conclusion The efficacy of SOF/VEL and/or with RBV in treating patients with CHC and CHC-precipitated liver diseases is good and promising, without severe untoward effects.

Key words: Hepatitis C, Sofosbuvir/velpatasvir, Real world, Efficacy, Safety